Croma-Pharma Presents New Cosmetic Skincare Brand "Croma farewell™" For Common Skin Conditions
Croma-Pharma (Croma) is opening a new chapter and expanding its product portfolio to meet the growing needs of its customers. With the innovative skincare brand Croma farewell™, the company is specifically addressing the desire of consumers for natural, effective and individual skincare and building upon its many years of experience in the production of hyaluronic acid. The name says it all: consumers say goodbye to their facial skin problems and hello to their new selves when using Croma farewell™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210531005179/en/
Croma farewell Range (Photo: Business Wire)
The Austrian produced brand will initially launch in all key markets with facial serums for five specific skin types.
High-quality care for specific skin conditions based on hyaluronic acid
Genetics, external factors and psychological influences can have a decisive impact on an individual’s skin condition and lead to various problems. Croma viewed this situation as an opportunity to develop a high-quality facial care line for specific skin needs: Croma farewell™.
The Croma farewell™ cosmetic portfolio of five different facial serums unites carefully selected ingredients with years of experience in the pharmaceutical and aesthetic field. Based on this expertise, all formulations contain a blend of both high and low molecular weight hyaluronic acid – an antioxidant that moisturizes and hydrates the skin, improves elasticity and smoothes and plumps the skin’s appearance to reduce fine lines and wrinkles.
All ingredients incorporated into the serums are carefully selected and based on scientific data to achieve the most effective results.
"With the launch of Croma farewell™, we are strengthening our focus on personalized skincare innovation, drawing on our many years of expertise as well as the latest scientific findings. Croma farewell™ meets the high standard of our medical products and perfectly complements our existing portfolio", explains Managing Director, Andreas Prinz.
Concentrated efficacy: 5 serums for 5 common facial skin conditions
farewell irritated skin: Target-specific face serum for irritated, sensitive skin with Hyaluronic Acid, Madecassoside, Niacinamide and D-Panthenol to sooth irritations, reduce skin redness and strengthen the skin barrier.
Perfume free. 30 ml.
farewell puffy eyes: A face serum, especially designed for the eye contour, to fight the appearances of puffiness, dark circles and crow's feet. The diligent formulation contains Hyaluronic Acid, D-Panthenol and a complex of Ash tree bark extract, organic silicon and Vitamin B3 for radiant, glowing skin and a fresher look.
Perfume free. 30 ml.
farewell dry skin: farewell dry skin contains hydrating ingredients including Hyaluronic Acid, Niacinamide, D-Panthenol and Aloe Vera to effectively nourish the skin and strengthen the skin barrier. Softens the skin and boosts elasticity.
Perfume free. 30 ml.
farewell aging skin: farewell aging skin is enriched with Hyaluronic Acid, Madecassoside, Vitamin C, Marine ferment extract and a plant-derived Retinol alternative to hydrate the skin and improve suppleness and firmness while effectively reducing the signs of aging.
Perfume free. 30 ml.
farewell oily skin: Formulated especially for oily and acne-prone skin, farewell oily skin contains a zinc complex and plankton extract to reduce blemishes and clogged pores, while diminishing the facial sebum production. Niacinamide and Wintergreen leaf extract regenerate the skin barrier for a softer skin and a glowing complexion.
Perfume free. 30 ml.
farewell follows clean beauty concept
More and more people attach great importance to responsible consumption. Croma farewell™ complies with this wish – all serums are vegan, free from silicones, perfumes, mineral oils and are developed and produced exclusively in Austria. The products are cruelty-free and contain no animal-derived ingredients.
Price and availability
The Croma farewell™ facial serums are available soon via the Croma skincare web shop www.cromaskincareshop.com and selected partners.
Recommended retail price: EUR 119,-.
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix To Highlight Success In Enabling Secure Virtual Hollywood Events at Variety Entertainment & Technology Summit16.9.2021 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Jon Samsel, Senior Vice President of Marketing, will discuss the value of harnessing security as a differentiator for the M&E industry during the upcoming virtual Variety Entertainment & Technology Summit. On Thursday, September 23, 2021 from 10:50 to 11:20 a.m. Pacific Time, Samsel will take part in a panel alongside Little Cinema Digital CEO Jay Rinsky and moderator Todd Spangler, NY Digital Editor at Variety. Register for free today. Titled, “Security That's Transforming Hollywood: The Little Cinema Digital Story,” the online event serves as an opportunity for attendees to learn how Verimatrix and Little Cinema Digital collaborated to transform the traditional Hollywood movie premiere business into an immersive virtual event platform that breaks down traditional limitations of venue capacities or locations. By leading with security, the comp
Exactech’s Equinoxe® Stemless Shoulder Replacement System Debuts in Europe16.9.2021 16:06:00 CEST | Press release
Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that the first anatomic total shoulder surgery has been performed in Europe using its bone-conserving, 3D-printed Equinoxe® Stemless Shoulder. Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany, performed the first surgery earlier this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005561/en/ Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany performed the first surgery in Europe using Exactech's bone-conserving, 3D-printed Equinoxe® Stemless Shoulder (Photo: Business Wire) “It was wonderful to be the first user of the Exactech Stemless humeral component in Europe,” Tauber said. “I’ve used stemless implants with various systems since 2007, so I know what we are talking about and have to congratulate Exactech for this product. The user-friendly in
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRAS G12C Inhibitor16.9.2021 14:00:00 CEST | Press release
Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The trial will investigate potential synergistic effects of this combination, possibly improving therapeutic outcomes beyond those of KRASG12C inhibitor therapy alone, specifically for people living with lung and colorectal cancers. Preclinical data suggest that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may result in increased anti-tumor activity in KRAS G12C-driven cancers based on the complementary mechanisms of these targeted oncology agents.1 2 By shifting the equilibrium from active KRAS towards the inactive form, SOS1::pan-KRAS inhib
SoftServe Wins Gold in 2021 Brandon Hall Group Excellence in Leadership Development Awards16.9.2021 13:05:00 CEST | Press release
SoftServe, a leading digital authority and consulting company has won Gold in the Best Advance in Coaching and Mentoring nomination at the 2021 Brandon Hall Group Excellence in Leadership Development Awards. The company was recognized for a unique learning ecosystem that implements mentoring and coaching practices to help associates grow, gain new competencies, and hone their leadership skills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005049/en/ SOFTSERVE WINS GOLD IN 2021 BRANDON HALL GROUP EXCELLENCE IN LEADERSHIP DEVELOPMENT AWARDS (Graphic: Business Wire) Individual-oriented learning at SoftServe is part of the corporate learning and development ecosystem. SoftServe University offers learning solutions in over 20 different formats. Besides trainings, long-term, conventional, and e-learning programs, mentoring and coaching enable associates to gain knowledge and experience faster, improving employee performanc
Entersekt Enables FIDO Authentication for Improved Security, User Experience, and Customer Choice16.9.2021 13:00:00 CEST | Press release
CYBER attacks pose a massive risk for financial institutions. The cost of data breaches averages tens of millions of dollars, and other after-effects are often far-reaching for organizations and their customers. At the root of these breaches are passwords – in an estimated 80% of cases. “Eliminating passwords and replacing them with more secure and user-friendly solutions is critical,” says Entersekt’s SVP Product, Christian Ali. Ali says there’s been a massive surge in online fraud in the past 18 months. Existing methods of authenticating consumers’ identities and transactions typically rely on outdated, less secure solutions like passwords or OTPs, while more secure solutions often require a mobile app. In addition, poor user experience often leads to cart abandonment – and lost sales. Users are frustrated and banks are at risk. To address the divide between strong security on the one hand and good user experience on the other, Entersekt has expanded its authentication suite to inclu
Philip Morris International Announces Unconditional Offer for Vectura Group PLC16.9.2021 11:48:00 CEST | Press release
PMI Global Services Inc. (PMI) (NYSE: PM) today announced that its offer for Vectura Group plc (Vectura) (LSE: VEC) has become unconditional, having received valid acceptances for or acquired 74.77 % of Vectura shares, in excess of the 50% required under the acceptance condition, as well as confirming that all other conditions to the offer have been satisfied or waived. PMI has extended the offer to allow for the tender of further shares. “We have reached an important milestone in our acquisition of Vectura and are pleased to have secured over 74% of the company’s shares, in excess of the 50% required to make our offer unconditional and PMI the majority shareholder," said PMI’s Chief Executive Officer, Jacek Olczak. "We are very excited about the critical role Vectura will play in our Beyond Nicotine strategy and look forward to working with Vectura’s scientists and providing them with the resources and expertise to grow their business to help us achieve our goal of generating at least
Argenta Acquires Top Clinical Research Organization Klifovet to Enhance Services and Expand Global Footprint16.9.2021 11:10:00 CEST | Press release
Argenta, the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health, announced today that it has acquired Klifovet, the leading CRO and Regulatory Affairs consultancy organization in Europe. Financial details of the transaction were not disclosed. Klifovet founder and CEO Dr. Klaus Hellmann will continue to lead Klifovet and will join Argenta’s senior leadership team. Founded in 1997 by Dr. Klaus Hellmann and located in Munich, Germany, Klifovet has built a leading reputation in the animal health industry, providing extensive expertise in clinical research and regulatory affairs. Its ~50 employees have had successful involvement in hundreds of studies, and their expertise and knowledge has been critical to numerous marketing authorizations for pharmaceutical, biological, immunological, and novel therapies. Its client base comprises the world’s top animal health and nutrition companies as well as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom